Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
BACKGROUND
Altered mineral metabolism in chronic kidney disease (CKD) is associated with increased morbidity, mortality, hospitalization, cost of care and reduced quality of life. Phosphorus control, one component of CKD metabolic derangements, is potentially related to impaired outcomes and has significant room for improvement.


METHODS
Historical, present and future aspects of treatment of hyperphosphatemia focusing on sevelamer hydrochloride and sevelamer carbonate.


RESULTS
Comprehensive insight into the background and controversies regarding phosphate binders.


CONCLUSIONS
While calcium-free phosphate binders with a sevelamer backbone may offer therapeutic advantages for CKD patients at risk, more studies comprising significant patient numbers are warranted to answer compelling clinical questions.
Biggar
Patrick
P
Klinikum Coburg, Nephrological Department, Ketschendorferstrasse 33, 96450 Coburg, Germany. patrick.biggar@klinikum-coburg.de
Ketteler
Markus
M
D000818:Animals; D002614:Chelating Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications*; D011073:Polyamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011788:Quality of Life; D012306:Risk; D000069603:Sevelamer
D002614:Chelating Agents; D011073:Polyamines; D000069603:Sevelamer